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Abstract
Humans who experience a primary dengue virus (DENV) infection develop antibodies that preferentially neutralize the
homologous serotype responsible for infection. Affected individuals also generate cross-reactive antibodies against
heterologous DENV serotypes, which are non-neutralizing. Dengue cross-reactive, non-neutralizing antibodies can enhance
infection of Fc receptor bearing cells and, potentially, exacerbate disease. The actual binding sites of human antibody on
the DENV particle are not well defined. We characterized the specificity and neutralization potency of polyclonal serum
antibodies and memory B-cell derived monoclonal antibodies (hMAbs) from 2 individuals exposed to primary DENV
infections. Most DENV-specific hMAbs were serotype cross-reactive and weakly neutralizing. Moreover, many hMAbs bound
to the viral pre-membrane protein and other sites on the virus that were not preserved when the viral envelope protein was
produced as a soluble, recombinant antigen (rE protein). Nonetheless, by modifying the screening procedure to detect rare
antibodies that bound to rE, we were able to isolate and map human antibodies that strongly neutralized the homologous
serotype of DENV. Our MAbs results indicate that, in these two individuals exposed to primary DENV infections, a small
fraction of the total antibody response was responsible for virus neutralization.
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Introduction
Dengue virus (DENV) complex consists of 4 serotypes. People
exposed to primary DENV infections develop robust antibody re-
sponses that cross-react with all serotypes (Reviewed in [1]). Des-
pite the extensive cross-reactivity, individuals only develop long
term, protective immunity against the homologous serotype re-
sponsible for the primary infection [2,3]. Indeed, the risk of pro-
gressing to DHF is greater during secondary compared to primary
infection [4]. A prevailing theory that explains severe dengue
during secondary infection is that pre-existing, non-neutralizing
dengue specific antibodies enhance DENV entry and replication
in Fc-receptor-bearing cells, which leads to a higher viremia and
more severe disease [4]. Antibodies have been demonstrated to
enhance DENV in cell culture [5,6] and in animal models of
dengue pathogenesis [7–9].
Our current understanding of how antibodies interact with
DENV and other flaviviruses is primarily based on studies utilizing
mouse monoclonal antibodies (MAbs) (Reviewed in [10]). The
DENV envelope (E) protein is the principle target of neutralizing
antibodies. Antibody neutralization occurs by blocking critical
functions of the E protein, including attachment to host cells and
low pH-dependent fusion of the viral and host cell membranes
[11]. The crystal structures of the E protein of several flavivi-
ruses have been solved [12–15]. Individual subunits of E protein
consist of three beta-barrel domains designated domains I (EDI), II
(EDII) and III (EDIII), with the native protein forming a head-to-
tail homodimer. Mouse MAbs that bind to all three domains
of DENV E have been generated and characterized [16–23].
Although neutralizing mouse MAbs have been mapped to all three
domains of E, the most strongly neutralizing MAbs recognize
epitopes on the lateral ridge and A strand of EDIII [24].
Following a primary DENV infection, humans develop anti-
bodies that cross-react with all 4 serotypes, but mainly neutralize
the homologous serotype responsible for the infection (Reviewed
in[3]). Studies with human immune sera and, more recently,
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nant antibody response is cross-reactive and weakly neutrali-
zing [25–30]. Multiple viral antigens including E protein, pre-
membrane (prM/M) protein and non-structural protein 1 (NSP1)
are recognized by the human humoral response [25–30]. None-
theless, few studies have defined the actual epitopes of DENV
recognized by type-specific and cross-reactive human antibodies at
the structural level and compared this to the epitopes defined using
mouse antibodies. The target(s) of dengue type-specific, strongly
neutralizing human antibodies remain unknown. The goal of
this study was to study two subjects in-depth to define the major
antigens and epitopes recognized by antibodies that develop
following primary human DENV infection. Defining the human
B-cell epitopes on DENV is a key step towards understanding how
antibodies can both enhance and inhibit the severity of DENV
infections.
Materials and Methods
Viruses, recombinant proteins and immune sera
DENV1 WestPac-74, DENV2 S-16803, DENV3 CH-53489, and
DENV4 TVP-360, provided by Dr. Robert Putnak (Walter Reed
Army Institute of Research, Silver Spring, MD) were used in the
present study [29]. Recombinant envelope (rE) proteins from the 4
DENV serotypes were kindly provided by Dr. Beth-Ann Coller
(Hawaii Biotech, Inc) [12]. The recombinant proteins bind to
conformational MAbs and X-ray crystallography studies have
demonstrated that these proteins retained a native-like structure
[12,13]. Convalescent DENV immune sera were obtained from
volunteers who had experienced natural DENV infections during
travel abroad. The protocol for recruiting and collecting blood
samples from people was approved by the Institutional Review Board
of the University of North Carolina at Chapel Hill. Written informed
consent was obtained from all subjects before collecting blood.
Whole DENV and recombinant E antigen ELISAs
ELISA plates were coated with 50 ng of purified virus or 100 ng
of rE in carbonate buffer at pH 9.6 for 2 hrs at room tempera-
ture and incubated with blocking buffer (0.05% TBS-T containing
3% skim milk or 3% normal goat serum) at 37
oC for 1 hr. Hu-
man immune sera or hMAbs serially diluted in blocking buffer
were added for 1 hr at 37uC followed by alkaline phosphatase-
conjugated goat anti-human IgG (Sigma) for 1 hr at 37uC. Finally,
p-nitrophenyl phosphate substrate (Sigma) was added to each well
and the reaction was allowed to develop for 15 minutes before
recording optical density at 405 nm on a spectrophotometer.
DENV Neutralization assays
DENV neutralizing antibodies was measured by a focus
reduction neutralization test (FRNT) with Vero cells or using a
flow cytometry-based neutralization assay with the U937 human
monocytic cell line stably transfected with DC-SIGN as previously
described [31].
Author Summary
Dengue is a mosquito-borne viral disease of humans. The
dengue virus complex is made up of four viruses designatedas
serotypes. People experiencing their first infection develop
immune responses that prevent re-infection with the same
serotype only. People experiencing a second infection with a
new serotype face a greater risk of developing a severe disease
known as dengue hemorrhagic fever. Although studies
indicate that antibodies can prevent or enhance disease
caused by DENV, few studies have explored the specific
properties of human antibodies against DENV. The objective
of this study was to conduct a detailed analysis oftheantibody
response of two individuals who had recovered from primary
infections. Human antibodies bound to sites on the dengue
virus particle including the viral pre-membrane (prM/M) and
envelope (E) proteins. Our studies indicate that the human
antibody response consists of a minor population of strongly
neutralizing antibody and a major population of DENV
serotype cross-reactive, non-neutralizing antibody with po-
tential for enhancement of virus and disease. Further studies
with more DENV-immune subjects are needed to determine if
our findings are broadly applicable to primary infections.
Table 1. Relative levels of virus and rE protein binding antibody in immune sera.
Serum Serotype End point binding titer
a rE antibody relative to
whole virus antibody (%)
b
Whole virus rE protein
Serum 013 (primary DENV2) DENV1 3,579 358 10
DENV2 8,906 1,536 17
DENV3 3,579 1,242 35
DENV4 3,141 485 15
Serum 033 (primary DENV3) DENV1 13,164 1,338 10
DENV2 8,906 2,050 23
DENV3 20,768 6,931 33
DENV4 12,334 1,815 15
aThe end point binding titers are based on ELISAs performed with virus or recombinant E (rE) protein antigen and serial dilutions of immune serum. The end point titer
was the reciprocal of the highest dilution that produced a signal 2 standard deviations above the signal for normal human sera.
bThe amount of antibody that bound to rE protein relative to the virus was calculated using the following formula: (end point titer for rE antigen/end point titers for
whole virus)X 100. When endpoint titers were calculated using a E protein cross reactive mouse MAb (4G2), similar end point titers were obtained for well coated with
virus or recombinant E indicating both antigens had a similar number of accessible E molecules.
doi:10.1371/journal.pntd.0001188.t001
Human Antibody Response to Dengue Infection
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immune travelers
Peripheral blood samples were obtained from two healthy
adult donors who were infected by DENV during foreign travel.
The dengue neutralization profiles confirmed previous primary
DENV2 (Donor 013) and DENV3 (Donor 033) infections (Table
S1). From both donor hMAbs were produced as previously des-
cribed [32]. B-cells producing DENV specific antibody were iden-
tified by screening culture supernatants by flow cytometry for
antibodies that bound to C6/36 insect cells infected with DENV2
(Donor 013) or DENV3 (Donor 033) [32]. A secondary screen to
identify antibodies that bound to the rE was performed by ELISA
as previously described [32].
Epitope mapping of EDIII binding hMAbs
DENV antibody escape mutant viruses were selected for by
infecting Vero cells with DENV2 (strain S-16803) in the presence
of hMAb concentrations estimated to neutralize greater than 99%
of infectious virus (i.e. 1.0 mg/ml for DVC 3.7 and 1.5 mg/ml
for DVC 10.16). Equivalent GC copy numbers of control and
antibody treated viruses were repeatedly passaged in the presence
of hMAbs until equivalent DENV genomic copy numbers were
observed for MAb treated and control samples (4–6 passages
under antibody pressure). Escape mutant viruses were plaque
purified and amplified. E genes were amplified by RT-PCR and
sequenced to identify mutations linked to antibody escape. Anti-
body binding sites were also mapped by using yeast cells expre-
ssing a library of EDIII as previously described [33]. Mutations
were mapped onto the DENV2 EDIII structure using the atomic
coordinates of DENV2 EDIII (RCSB accession number 1OAN)
and displayed using PyMOL Molecular Graphics System, Version
1.3 (Schro ¨dinger, LLC).
Results
The objective of the current study was to characterize the
primary human antibody response to DENV by comparing
immune sera and MAbs derived from two individuals previously
exposed to primary DENV infections. Donor 033 had reported
a high fever following a visit to India in 2005 and laboratory
investigations confirmed a primary DENV3 infection (data not
shown). One year later, when serum and peripheral blood mono-
nuclear cells (PBMCs) were isolated, the subject had a neutralizing
antibody response that primarily targeted DENV3 (Table S1).
Donor 013 developed a fever, clinically diagnosed as dengue,
while visiting a Pacific Island in 1996. Eight years later when
serum and PBMCs were isolated for the current study, the subject
had a neutralizing antibody profile consistent with a past primary
DENV2 infection (Table S1).
Initially we characterized the binding properties of serum
polyclonal antibodies in both subjects using purified DENVs
and recombinant DENV E proteins from the 4 serotypes. We
calculated endpoint titers (reciprocal of highest serum dilution that
was positive in the assay) to estimate relative levels of antibody
against whole virus and rE antigens (Table 1). The quantity of
antibody binding to E was only 10 to 35% of the quantity that
bound to whole virus suggesting that antibodies bound to sites on
the virus that were not present on rE protein (Table 1). Thus, in
both subjects the predominant antibodies binding to dengue
virions were serotype cross-reactive and directed to epitopes on the
virus and, to a lesser extent, to epitopes on rE protein.
Identification of DENV-reactive memory B cells following
primary infection
We have previously reported that dengue reactive memory B
cells are common following both primary and secondary DENV
infection [30]. To further characterize the human B cell response
in donor 033, we immortalized memory B cells. PBMCs were
isolated and IgG+ memory B cells were immortalized with EBV
and CpG as previously described [34]. The immortalized B cell
culture supernatants were screened for antibodies that bound to
C6/36 insect cells infected with DENV3. Thirty five percent of the
B cell cultures generated from donor 033 were positive following
this initial screen (Table 2). From the dengue positive cultures only
7.5% of the cultures bound to rE protein (Table 2). To further
characterize the binding and functional properties of human
antibodies, we isolated hMAbs from donor 033.
Table 2. Screen for isolating DENV-specific human Mabs.
Donor
No. of positive cultures
after primary screen
a
Proportion of DENV positive
cultures binding to rE protein
b
No. of human
MAbs produced
c Reference
033 (primary DENV3) 332/960 (35%) 7.50% 16 This study
013 (primary DENV2) 567/2016 (28%) 2.90% 10 Betramello et al 2010
aPrimary screen was conducted by flow cytometry using C6/36 cells infected with the homologous serotype.
bProportion of recombinant E (rE) protein reactive cultures was determined by ELISA using recombinant protein from homologous virus.
cFor donor 013, the selection of cultures for DENV-specific MAb production was biased to enrich for rE and EDIII reactive MAbs.
doi:10.1371/journal.pntd.0001188.t002
Figure 1. Antigens recognized by hMAbs produced from donor
033. DENV3 virions were purified and the viral proteins were separated
by SDS-polyacrylamide gel electrophoresis. Western blots were
performed to identify the viral antigens recognized by hMAbs from
donor 033. The figure displays Western blot results for selected hMAbs
that bound to E protein (64.31) and prM protein (DV38.1, 59.3, 65.5, 4.3,
11.12, and 18.5). 4G2 and 2H2 are control mouse MAbs that bind E and
prM proteins, respectively.
doi:10.1371/journal.pntd.0001188.g001
Human Antibody Response to Dengue Infection
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To isolate hMAbs specific for DENV from donor 033, positive
B cell cultures were cloned by limiting dilution and 16 clones were
isolated and expanded. All the hybridomas produced IgG1 with
the single exception DV20.10, which was IgG3 (Table S2). To
identify antibodies that bound to structural viral antigens, the
hMAbs were tested for binding to purified DENV3 particles in
ELISA. Fourteen out of 16 hMAbs bound to DENV3 virus. Of the
14 hMAbs that bound to DENV3 particles, 13 cross-reacted with
all four dengue serotypes dengue complex reactiveand one anti-
body (hMAb DV51.3) bound to serotypes 1 and 3, but not 2 and 4
(dengue sub complex reactive)(Table S2). Dengue virions were
solubilized and subjected to Western blot analysis to identify
the viral structural proteins recognized by hMAbs. Ten of the
14 hMAbs bound to prM and only a single hMAb (DV64.3)
bound to E protein (Figure 1). Three hMAbs did not bind to viral
antigens by Western blot, although they reacted with DENV3
virion. The 16 hMAbs were also tested for binding to rE protein in
ELISA. Only hMAb DV64.31, which had also recognized E
protein by Western Blot, bound to rE protein from all 4 DENV
serotypes (Table S2).
We next tested the ability of the 16 antibodies generated from
donor 033 to neutralize DENV. Five hMAbs including the two
that did not bind to the virion lacked neutralizing activity
(Figure 2). The remaining antibodies ranged from weak to
moderately neutralizing and had DENV3 50% neutralization
titers that ranged from 0.09 to 1 mg/ml (Figure 2A). The
neutralizing antibodies had similar 50% neutralization titers
against all 4 serotypes, which was consistent with their broad
binding specificity (data not shown). In general, prM antibodies
had neutralization curves that were shallow and did not reach
100% neutralization, indicating that a fraction of the virus popu-
lation was resistant to antibody neutralization (Figure 2B). The
single E reactive antibody (DV64.31) exhibited a steeper neutra-
lization curve and neutralized 100% of virus at high concentra-
tions (Figure 2C). In summary, the hMAbs generated from donor
033, who had experienced a primary DENV3 infection, were
broadly cross-reactive, weakly neutralizing, and mainly directed to
epitopes on prM. None of the hMAbs mimicked the functional
properties of immune serum from donor 033 that displayed strong
type-specific neutralization of DENV3 (Table S1). A complete
summary of the functional profiles of all sixteen hMAbs from
donor 033 is included as supplementary material (Table S2).
Characterization of Human MAbs generated from donor
013
Next, we characterized the dengue specific memory B cell
response in donor 013, who had recovered from a primary
DENV2 infection. We have previously reported on some of the
Figure 2. DENV3 neutralization by donor 033 human MAbs. The 50% neutralization titers against DENV3 were determined for all 16 hMAbs
from donor 033 using a flow cytometry based neutralization test that utilizes U937 cells expressing DC-SIGN. (A) Dengue antigen recognized and the
50% neutralization titer for each hMAb. The hMAbs for which a specific antigen has still not been identified are designated with a *?*. (B)
Neutralization curves for three representative prM antibodies. Note that prM antibodies have shallow neutralization curves, which plateau when
,60% of the virions are neutralized. (C) Neutralization curve of the only E protein reactive antibody obtained from donor 033. This antibody has a
steeper neutralization curve compared to prM antibodies.
doi:10.1371/journal.pntd.0001188.g002
Human Antibody Response to Dengue Infection
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Here we expand on these previous results by comparing properties
of serum antibodies and hMAbs from this donor and by epitope
mapping a subset of hMAbs from this donor. When immortalized
B cell culture supernatants from donor 013 were screened for
antibodies that bound to C6/36 insect cells infected with DENV2,
28% (567/2016) of the cultures were found positive for DENV-
specific B cells following this initial screen (Table 2). From the
DENV positive cultures only 2.9% of the cultures bound to rE
protein (Table 2). Thus, as in the case of donor 033, although
dengue specific memory B cells were frequent, only a small frac-
tion of the positive cultures from donor 013 produced antibodies
that bound to rE protein.
Since a relatively unbiased selection scheme for producing
hMAbs from donor 033 indicated that most hMAbs were cross-
reactive, weakly neutralizing and directed to antigens other than
rE, we altered the selection scheme for donor 013 to enrich for
hMAbs that recognized rE from DENV2. After the initial scree-
ning of memory B cell culture supernatants, the relatively rare rE
protein binding cultures were selected for cloning and expansion.
Ten rE binding hMAbs were produced (all IgG1). When the anti-
bodies were tested for binding to heterologous serotypes, 5 hMAbs
were DENV2 type-specific, 2 hMAbs were dengue subcomplex-
specific and 3 hMAbs were dengue complex-specific (Figure 3A).
Six of the ten hMAbs bound to EDIII from DENV2 (Figure 3A).
The hMAbs from donor 013 displayed variable neutralization
properties (Figure 3A–C), with 2 non-neutralizing hMAbs (DV1.6,
and 21.5; 50% neutralization titers .1 ug/ml) , 4 weakly to mode-
rately neutralizing hMAbs (DV14.21, 35.3, 25.5 and 18.21; 50%
neutralization titers between 0.1 and 1 ug/ml) and 4 strongly
neutralizing hMAbs (DV3.7, 10.16, 13.6 and 23.13; 50% neutra-
lization titers ,0.1 ug/ml). The strongly neutralizing hMAbs, in-
cluding those that were cross-reactive in binding assays, neutral-
ized DENV2 better than the other serotypes (Figure 3). Thus, by
biasing the initial screen for hMAbs that bound to rE protein, we
identified hMAbs with neutralization profiles that were more
similar to the immune sera of donor 013, which strongly neutra-
lized DENV2.
Epitope mapping donor 013 hMAbs binding to EDIII
Several hMAbs from donor 013 bound to EDIII (Figure 3). Two
approaches were used to map the binding sites of these hMAbs
on EDIII. Two strongly neutralizing hMAbs that bound EDIII,
which were type- (DV3.7) or subcomplex- (DV10.16) specific,
were mapped by identifying neutralization escape variants after
passaging DENV2 in the presence of each antibody (ired a
mutation on EDIII. The virus passaged in the presence of hMAb
DV3.7 acquired the single point mutation V382G (Table 3 and
Figure 4C). This residue is located on the EDIII lateral ridge,
which is a target of previously mapped type-specific strongly
Figure 3. Binding and neutralization properties of donor 013 hMAbs. Ten hMAbs from donor 013 were tested for binding dengue virus,
recombinant E (rE) and EDIII from DENV2. Cross-reactivity was determined by using whole virus antigen from all four serotypes. For each hMAb the
50% neutralization titer was determined using flow cytometry and U937 cell expressing DC-SIGN. (A) Summary of the binding and neutralization data
for all hMAbs from donor 013. B, C and D display representative neutralization curves for DENV2 type-specific (B), subcomplex- specific (C) and
complex-specific (D) hMAbs.
doi:10.1371/journal.pntd.0001188.g003
Human Antibody Response to Dengue Infection
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virus passaged in the presence of hMAb DV10.16 acquired the
point mutation E311K (Table 3 and Figure 4C). This amino acid
is located on the A strand of EDIII and forms part of a dengue
subcomplex epitope recognized by neutralizing mouse MAbs
[18,23] (Table 3 and Figure 4C).
As an independent approach to mapping EDIII-reactive
hMAbs, we used a yeast surface display assay that has been
previously used to map numerous flavivirus antibodies [22,23,33].
Table 3 summarizes all mutations that resulted in loss of binding
or neutralization of EDIII antibodies generated from donor 013.
All the human EDIII-binding MAbs mapped to the lateral ridge
Table 3. Epitope mapping DENV2 EDIII reactive MAbs from donor 013.
Human MAb
(Donor 013)
a
Binding
specificity
b
DENV2 neutralization
potency
c
Neutralization
escape mutations
d
DENV2 Yeast
EDIII mapping
e
EDIII Epitope
Loss of binding Decreased binding
DV3.7 DENV2 type specific Strong V382G P384A, P384N K307Q DIII-lateral
DV14.21 DENV2 type specific Weak NA K305E, K307N,
K307I, K310E
G304Y K307Q DIII-A strand
DV25.5 DENV2 type specific Moderate NA T303Y, G304Y,
K307N, K307Q
D329Q, G330D,
E383G, P384A, P384N
DIII-lateral
DV10.16 DENV subcomplex Strong E311K K305E, K310E NA DIII-A strand
DV21.5 DENV complex None NA K305E, K310E, K317Y NA DIII-A strand
NA = Not Applicable
aOnly EDIII reactive MAbs from donor 013 were mapped.
bThe MAbs were tested for binding to the four DENV serotypes.
cNeutralization potency is based on 50% neutralization titers in Figure 3.
dDENV2 escape mutants were obtained with strongly neutralizing MAbs only.
eEDIII mutations that led to a complete loss of binding and partial loss of binding are indicated separately.
doi:10.1371/journal.pntd.0001188.t003
Figure 4. Epitope mapping of anti-DENV2 hMAbs binding to EDIII. To identify antibody binding sites, DENV2 was serially passaged in the
presence of neutralizing hMAbs DV3.7 or DV10.16. Viruses growing in the presence of hMAbs were plaque purified and expanded. Neutralization
escape was confirmed by growing the parental and the cloned antibody selected viruses in the presence of each hMAb 3.7 (A) or hMAb 10.16
(B). (C) Localization of neutralizing human antibody epitopes on the structure of DENV2 EDIII (strain 16681) using residues identified by
neutralization escape selection (blue) or yeast surface display screening (see Table 3) (orange). Ribbon diagram of DENV-2 EDIII was generated from a
published X-ray crystallographic structure. The disulfide bond is highlighted in yellow. Human MAbs 3.7 and 25.5 are type-specific antibodies that
bind to epitopes centered on the lateral ridge while 10.16 is sub-complex-specific and bind to an epitope centered on the A strand of EDIII.
doi:10.1371/journal.pntd.0001188.g004
Human Antibody Response to Dengue Infection
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targets of mouse MAbs [23] (Figure 4C).
Discussion
Our main objective was to define viral antigens and epitopes
recognized by 2 individuals exposed to primary DENV infections.
In both these subjects the dengue virion was a major target of the
humoral immune response but many of these antibodies did not
bind to rE protein. The DENV virion displays 180 E and 180 prM
or M proteins that are arrayed with pseudo-icosahedral symmetry.
Depending on the maturation state of the virus particle, the 180 E
protein molecules are organized as 90 head-to-tail dimers that lie
flat on the virion surface or 60 trimers that protrude as spikes from
the surface [35]. Since the E protein, with ,500 amino acids, is
considerably larger than the 166 amino acid prM protein, the
majority of surface exposed viral protein consists of the ecto-
domain of E. Thus, our finding that many antibodies bound to
epitopes on the virus that were not preserved on rE was somewhat
unexpected. These findings are consistent with the results of
another study from our group [30] as well as a study by Dejni-
rattisai and colleagues who observed that many hMAbs that
bound to DENV particles did not bind to rE protein [25]. As the
rE protein used in the current study lacked ,20% of the protein,
which include the membrane proximal regions and the trans-
membrane domains, it is possible that some antibodies bind to
these regions. Moreover, antibodies may recognize E protein
epitopes that are only available in the context of the native
oligomeric array on the virion. Several hMAbs generated from
individuals infected with West Nile virus bound the virion but not
rE protein; these hMAbs recognized epitopes that were created by
adjacent E protein molecules on the surface of the virion or
formed by hinge regions [36].
When producing MAbs from donor 013, we increased the pro-
bability of identifying strongly neutralizing antibodies by biasing the
selection scheme for MAbs that specifically recognized rE protein.
In contrast to the weak or non-neutralizing hMAbs isolated from
donor 033, several hMAbs from donor 013 displayed strong type-
specific DENV2 neutralization. Of note, even hMAbs from donor
013 that bound to more than one serotype (dengue subcomplex or
complex MAbs) displayed type-specific neutralization of DENV2,
which was the serotype that infected donor 013. Thus, by biasing
the selection to enrich for rare rE protein binding antibodies, we
generated hMAbs from donor 013 that were functionally similar to
the polyclonal immune serum from the same donor that neutralized
only DENV2. It is unclear how the results with hMAbs relate to the
neutralization properties of polyclonal immune serum from these
donors. One possibility is that the abundance of hMABs reflects the
functional properties of antibodies in immune sera, where a small
fraction of DENV-specific antibodies in immune sera are respon-
sible for neutralization. Alternatively, it is conceivable that indivi-
dual antibodies that are weakly neutralizing become strongly neu-
tralizing due to cooperative effects that only occur in a polyclonal
milieu. Further studies are needed to understand how the properties
of hMABs from DENV immune donors relate to the properties of
circulating serum antibody.
From the neutralizing MAbs from donor 013 that bound to rE,
some bound to the lateral ridge and A strand epitopes on EDIII
(ref) . We also identified several neutralizing hMABs (35.3, 18.21,
13.6, 23.13) that bound to rE but not EDIII and these antibodies
most likely bind to epitopes on EDI or EDII. We are especially
interested in mapping the binding sites of these hMABs as recent
studies indicate that epitopes other than the lateral ridge and A
strand of EDIII can be the targets of strongly neutralizing mouse,
horse and primate antibodies [29,37,38,7,22],
Our results indicating that prM was a dominant target of the
primary antibody response are in agreement with other recent
studies [25,30]. The prM protein is required for the proper folding
and assembly of flavivirus particles in the endoplasmic reticulum
[39], while also preventing adventitious fusion of the virus [40] in
the acidic environment of the trans-Golgi network. Recent studies
have demonstrated that DENV virions produced in cell culture are
often partially processed and contain a mixture of unprocessed
prM and fully processed M [41]. The maturation state and relative
amount of prM on a virion can alter the potency of antibodies that
bind specific epitopes on E, including the cross-reactive antibodies
that bind the fusion loop in DII [42]. Additionally, immature, non-
infectious particles became infectious in the presence of prM
antibody by enhancing the ability of immature dengue virions to
infect Fc-receptor bearing cells in vitro [25,43]. Given our findings
and those of others [25] establishing that prM antibodies are
common following primary and secondary DENV infections,
more work needs to be performed to address their contribution to
dengue pathogenesis in humans.
In summary, the studies reported here demonstrate an unex-
pected antibody profile in two individuals following primary
dengue infection. In both individuals a majority of the DENV-
specific human antibodies were broadly cross-reactive and weakly
neutralizing. Many antibodies bound to prM and sites on the virus
that were not preserved on rE protein. Only a minor fraction of
the total dengue specific antibody response was responsible for
potent neutralization of the homologous virus. Given the difficulty
of identifying suitable donors and generating antigen specific
hMAbs, we only characterized the antibody response in two sub-
jects here. Further studies with more dengue immune subjects are
needed to determine if our findings are broadly applicable to
primary dengue exposure.
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